Bioxyne Eyes $75M Revenue with German Cannabis Contract Boost

Strong Growth Outlook for FY2026

Bioxyne Limited (ASX – BXN) has released its full-year guidance for FY2026, forecasting revenues between $65 million and $75 million, alongside an EBITDA range of $11.5 million to $13.5 million. This optimistic outlook is underpinned by the company’s expanding footprint in the Australian medical cannabis market and a strategic push into international territories.

Domestic Momentum and Contract Wins

At the core of Bioxyne’s growth is its subsidiary Breathe Life Sciences (BLS), which continues to secure new contracts and see increased order volumes from existing Australian clients. The company’s contract manufacturing services, including pastilles, flower packing, and liquid forms such as vapes and oral oils, each contribute roughly a third of revenues. This diversified product mix positions Bioxyne well to capitalize on rising demand for therapeutic cannabis products.

International Expansion Accelerates

Significantly, Bioxyne has made its first major inroad into the European market with a $5.8 million contract in Germany. The initial shipment is scheduled for September 2025, with a second delivery planned for November, reflecting a substantial increase in volume from 580kg to 1,550kg. This milestone marks a critical step in Bioxyne’s strategy to expand beyond Australia into high-growth markets including the UK and other EU countries.

Beyond Germany, BLS operates across multiple international hubs including the UK, Japan, and Czechia, offering contract manufacturing, wholesale distribution, and direct sales of consumer health brands such as Dr Watson®. The company’s global supply chain sources raw materials from five continents, underscoring its ambition to be a leading player in alternative therapeutics and investigational medicines worldwide.

Looking Ahead

Bioxyne’s FY2026 guidance reflects confidence in both organic growth and strategic international contracts. The anticipated contribution from resale of flower active pharmaceutical ingredients (API) and GMP-packed final products is expected to further bolster revenues. While the company has not disclosed detailed cost structures or capital expenditure plans, the focus on contract manufacturing and international expansion suggests a scalable business model with significant upside potential.